Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...
CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS is expected to come in at $2.04 in the third quarter, according to a company-compiled consensus ...
That is the Spanish name of a new Netflix documentary about the Spanish players’ reaction to the scandal — in English ...
“Until such point, we would caution people from drawing too many parallels between this and the bribery scandal that reared ...
Similarly, whilst GlaxoSmithKline’s origins can be traced ... increased on both sides of the Atlantic. The Thalidomide scandal of 1961 prompted an increase in the regulation and testing of ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...
Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.
Ben Hargreaves examines the reasons supplied by the survey and why GSK is invested in the answers. The emergence of COVID-19 meant that public awareness around vaccination and its importance in ...
Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback